Amavu n'amavuko

Ezetimibe ni ikintu gikomeye kandi kibuza kwanduza cholesterol [1].

Cholesterol ni molekile ya lipide kandi irasabwa kubaka no kubungabunga ibibumbano byuzuye kandi bitemba. Ikora kandi, ibanziriza vitamine D, aside aside na hormone steroid.

Mu ngirabuzimafatizo zitandukanye za Caco-2 zashyizwemo karotenoide (1 μM), ezetimibe (10 mg / L) yabujije gutwara karotenoide hamwe na 50% yabujije ɑ-karotene na β-karotene. Nanone, yabujije gutwara β-cryptoxanthin, lycopene na lutein: zeaxanthin (1: 1). Muri icyo gihe, ezetimibe yabujije gutwara cholesterol 31%. Ezetimibe yagabanije imvugo yakira hejuru SR-BI, ATP ihuza cassette itwara abantu, mu buryo butemewe A (ABCA1), Ubwoko bwa Niemann-Pick C1 Nka poroteyine 1 (NPC1L1) hamwe na reseptor acide retinoide (RAR) γ, ibintu bya sterol-bigenga poroteyine SREBP -1 na SREBP-2, hamwe n'umwijima X wakira (LXR) β [3].

Muri apolipoprotein E knockout (apoE - / -) imbeba, ezetimibe (3 mg / kg) yabujije kwinjiza cholesterol 90%. Ezetimibe yagabanije cholesterol ya plasma, yongera urwego rwa HDL, kandi ibuza iterambere rya ateriyose [1]. Mu cyiciro cya III cyibigeragezo byabantu, Ezetimibe (mg 10) yagabanije cyane urugero rwa cholesterol ya LDL, cholesterol yose hamwe na triglyceride kandi byongera urugero rwa cholesterol ya HDL [2].

Reba:
[1]. Davis HR Jr, Compton DS, Hoos L, n'abandi. Ezetimibe, inhibitori ya cholesterol ikomeye cyane, ibuza iterambere rya aterosklerose mu mbeba za ApoE knockout. Arterioscler Thromb Vasc Biol, 2001, 21 (12): 2032-2038.
[2]. Clader JW. Ivumburwa rya ezetimibe: kureba hanze ya reseptor. J Med Chem, 2004, 47 (1): 1-9.
[3]. Mugihe cya A, Dawson HD, Harrison EH. Ubwikorezi bwa Carotenoid bwaragabanutse kandi imvugo yabatwara lipide SR-BI, NPC1L1, na ABCA1 ntigabanywa muri selile Caco-2 ivurwa na ezetimibe. J Nutr, 2005, 135 (10): 2305-2312.

Ibisobanuro

Ezetimibe (SCH 58235) ni inhibitori ya cholesterol ikomeye. Ezetimibe ni inhibitor ya Niemann-Tora C1-isa na1 (NPC1L1), kandi ni Nrf2 ikomeye.

Muri Vitro

Ezetimibe (Eze) ikora nka enterineti ikomeye ya Nrf2 idateye cytotoxicity. Ezetimibe yongerera transactivation ya Nrf2, nkuko byagaragajwe numunyamakuru wa luciferase. Ezetimibe kandi igenzura ingirabuzimafatizo za Nrf2, zirimo GSTA1, heme ogisijene-1 (HO-1) na Nqo-1 muri selile Hepa1c1c7 na MEF. Ezetimibe igenga genes ya Nrf2 muri selile ya Nrf2 + / + MEF, mugihe iyi induction yahagaritswe rwose muri selile Nrf2 - / - MEF. Ufatiye hamwe, Ezetimibe akora nk'igitabo Nrf2 inducer muburyo bwa ROS [1]. Umuntu huh7 hepatocytes yateguwe na Ezetimibe (10μM, 1 h) hamwe na acide palmitike (PA, 0.5 mM, 24 h) kugirango itere umwijima. Ubuvuzi bwa Ezetimibe butuma cyane PA yiyongera kuri triglyceride (TG), ibyo bikaba bihuye nubushakashatsi bwinyamaswa. Ubuvuzi bwa PA bwatumye hafi ya 20% igabanuka rya mRNA imvugo ya ATG5, ATG6, na ATG7, yariyongereye no kuvura Ezetimibe. Byongeye kandi, kuvura Ezetimibe byongereye cyane kugabanuka kwa PA kugabanuka kwa poroteyine ya LC3 [2].

MCE ntabwo yemeje ubwigenge ubu buryo. Nibisobanuro gusa.

Ubuyobozi bwa Ezetimibe (Eze) bugabanya uburemere bwumwijima bwimbeba zagaburiwe indyo ya methionine- na choline ibura (MCD). Ibi bihuye ningaruka nziza za Ezetimibe kuri steatose ya hepatike. Amateka y’umwijima yerekana ibinure byinshi bya macrovesicular yibinure byimbeba ku ndyo ya MCD, ariko kuvura Ezetimibe bigabanya cyane umubare nubunini bwibyo bitonyanga. Byongeye kandi, fibrosis ya hepatike mu mbeba yagaburiwe indyo ya MCD ihuza cyane na Ezetimibe [1]. Urwego rw'amaraso n'umwijima birimo TG, aside irike yubusa (FFA), hamwe na cholesterol yuzuye (TC) byagabanutse cyane mumbeba za OLETF zavuwe na Ezetimibe. Byongeye kandi, imbeba za OLETF zerekana serumu nyinshi za glucose, insuline, HOMA-IR, TG, FFA, na TC kurusha inyamaswa za LETF, zigabanuka cyane na Ezetimibe. Byongeye kandi, isesengura ry’amateka ryerekanye ko imbeba zo kugenzura OLETF zerekanaga ibitonyanga binini bya lipide muri hepatocytes kuruta imyaka LETO igenzurwa n’imyaka, ibyo bikaba byerekanwa n’ubuyobozi bwa Ezetimibe [2].

Ububiko

Imiterere yimiti